Welcome to our dedicated page for Radnostix news (Ticker: INIS), a resource for investors and traders seeking the latest updates and insights on Radnostix stock.
Radnostix, Inc. manufactures radioisotope-focused products for medical, industrial and research applications and trades on the OTCQB under INIS. The company, formerly International Isotopes Inc., supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer, provides contract drug manufacturing and radioisotope API supply for theranostics clients, and sells calibration and reference standards for nuclear pharmacies, SPECT/PET imaging systems and industrial users through RadQual.
Recurring updates cover operating and financial results across Theranostics Products, Calibration & Reference Products, Nuclear Medicine Standards, Medical Devices and Cobalt Products, along with raw-material supply conditions, product-line updates for EasyFill and RadVent, and the completed corporate rebrand to Radnostix.
Radnostix (OTCQB: INIS) reported FY2026 Q1 revenue of $2.38 million, down 27% from $3.24 million, mainly due to voluntary product recalls, isotope supply disruptions, and Cobalt-60 downtime. Gross profit fell 43% to $1.15 million, and net loss widened to $1.35 million.
Operating expenses rose 7% to $2.46 million, and Adjusted EBITDA declined to $(0.92) million from $0.12 million. Radnostix completed a new Calibration & Reference Products facility with an initial NRC license amendment, repaired and restarted its Cobalt-60 hot cell, and regained control of DUF6 assets after mutually terminating the sale agreement.
Radnostix (OTCQB: INIS) reported fiscal 2025 revenue of $13.07 million, the second-highest in company history, with Calibration & Reference Products sales up 21% to $4.25M and Theranostics revenue of $6.84M. The company posted positive operating cash flow of $620,000 and completed facility upgrades, a hot cell refurbishment extending asset life 15–20 years, and an initial NRC license amendment for a new calibration facility. Radnostix retained DUF6 assets after mutually terminating a sale agreement and plans product launches in 2026.
Radnostix (NASDAQ:INIS) and American Fuel Resources mutually terminated the Asset Purchase Agreement dated February 8, 2024 for Radnostix's DUF6 deconversion and fluorine extraction plant, announced March 16, 2026. The buyer requested a one‑year extension but could not meet the March 31, 2026 outside date, and the parties withdrew the NRC transfer application and ended the sale.
The transaction would have included a $12,450,000 closing payment; AFR previously made non‑refundable payments totaling $170,000. As a result, Radnostix will not receive the balance of the purchase price, will not recognize sale gains, and will evaluate options for the DUF6 assets.
Alpine Income Property Trust (NYSE: PINE) will release fourth quarter and full year 2025 financial and operating results after market close on Thursday, February 5, 2026. A conference call to discuss results is scheduled for Friday, February 6, 2026 at 9:00 AM ET with a live webcast available on the company Investor Relations website. Participants are encouraged to register in advance for dial-in details and to join at least 15 minutes early. A replay of the earnings call will be archived on the company website. Contact for investor inquiries is ir@alpinereit.com. The company invests in single-tenant net-leased commercial properties leased predominantly to publicly traded, credit-rated tenants.
Radnostix, Inc. (formerly International Isotopes Inc., ticker INIS) filed a Certificate of Amendment in Texas to change its legal name to Radnostix, effective December 31, 2025, and will immediately begin rebranding operations under the Radnostix name.
The company said its operations, management team, and customer commitments remain unchanged. Current brands Radqual, Radvent, Easyfill, Benchmark, and PhanQual will continue under the Radnostix umbrella. Common stock will continue trading under INIS on the OTCQB for now; any ticker change will be announced later. Shareholders need not take action on stock certificates.
Radnostix manufactures radioisotope and theranostics products including I-131 drug product, calibration standards, and Cobalt-60 sealed sources. For more information, visit radnostix.com.
International Isotopes (OTCQB: INIS) reported Q3 2025 product revenue of $3,277,816 (down 16% YoY) and nine-month revenue of $10,172,036 (up 2% YoY) for the period ended September 30, 2025. The company posted a Q3 net loss of $203,601 versus a prior-year profit and a nine-month net loss of $477,080 (loss widened by $237,245).
Management attributed declines mainly to raw-material outages that reduced revenue by >$400,000 in Q3 and >$750,000 for nine months, while SG&A fell 24% for the quarter and 11% year-to-date. Nine-month EBITDA was $14,985 (vs. $210,590 prior year).
International Isotopes (OTCQB: INIS) reported improved financial results for Q2 and H1 2025. Product sales increased 15.3% to $3.66M in Q2 and 13.5% to $6.89M in H1 2025. The company reduced its net loss by 27% to $160,785 in Q2 and by 29.4% to $273,479 in H1 2025.
Performance highlights include 99% growth in Nuclear Medicine Standards revenue to $2.34M, driven by resolving the Cobalt-57 isotope shortage. Theranostics Products revenue declined 9% to $3.69M due to customer losses. The company received FDA approval for an additional raw material supplier and launched a new Medical Devices segment generating initial revenue of $58,089.
International Isotopes (INIS) reported strong financial results for Q4 and fiscal year 2024. Q4 revenues increased 24% to $3.9 million, while full-year revenues reached a historic high of $13.9 million, up 13% year-over-year. The company achieved significant profitability improvements, with Q4 net income rising 325% to $245,819 and full-year net income turning positive at $8,574.
The company's performance was driven by growth in Theranostics Products, which saw a 17% annual increase to $8 million, and record revenue in Cobalt Products, up 128% to $2.4 million. However, Nuclear Medicine products experienced a 20% decline due to raw material shortages. The company's new Medical Devices segment is preparing for product commercialization in 2025.
Non-GAAP EBITDA improved by 332% to $615,934, while adjusted EBITDA reached $1.2 million, a 379% increase from 2023.
International Isotopes (OTCQB: INIS) has announced a strategic expansion of its operational footprint through two key moves in Idaho Falls. The company has acquired vacant land adjacent to its current facility (Building A) and entered into a lease agreement for a second building (Building B) located across the street, which includes a purchase option.